new study phases may take less time to complete and have more customers than finishing just phase 3
From Seeking Alpha Jan, 16,2013,,,,"Ixmyelocel-T has several features that are critical for success in treating patients suffering from a complex, multi-factorial, severe and chronic diseases such as critical limb ischemia ((CLI)) or dilated cardiomyopathy ((DCM))."
Thats phase 2 ,,big deal, so maybe its safe..Now tell me where the money is going to come from ?
Phase 3 should be completed by 2019? LOL
The pump here is getting hilarious.
LMAO especialy at the Chairman